Which repair result are we actually comparing?
More collagen. A stronger tendon. No serious side effects reported. All sound encouraging, but they mean different things. Here's how we keep a promising result from growing beyond its study.
Start with the cells
In the GHK-Cu collagen experiment, researchers grew human fibroblasts in dishes. These cells make the material around cells, including collagen, a protein that gives tissue structure. GHK-Cu increased collagen production. The word human describes the cells, rather than people receiving treatment.
That small distinction does a lot of work. The study doesn't tell us how much of an ingredient reaches someone's skin, whether an injury heals faster or whether a person feels better. It answered a useful lab question. Those bigger questions need their own tests.
Then look at the tendon
The BPC-157 rat study went further than measuring tissue material. Researchers cut Achilles tendons and assessed healing, including strength and function. They found improvements. For a repair question, it's useful to know whether the repaired tissue can do its job.
Now comes the next gap: a rat with a deliberately cut tendon isn't a person with a sore tendon that won't settle. The injury and the species matter. The FDA's BPC-157 review leaves human safety and effectiveness unresolved; the rat result can't settle them.
Check which peptide was tested
Before borrowing a result for TB-500, there's an identity problem to sort out. The FDA found no published human studies giving TB-500 to people. TB-500 is a short fragment of thymosin beta-4, rather than the full peptide.
A small study in healthy volunteers gave full-length thymosin beta-4 into a vein and reported no serious adverse events. That result belongs to the full peptide and that short study. It didn't test TB-500, injury repair or GLOW. A shared family name doesn't transfer the finding.
Leave space for what we don't know
These examples aren't a contest with a winning ingredient. The studies asked different questions. To compare treatments usefully, we'd want the same condition, a fair comparison, outcomes that matter to people and a careful account of harm.
A review of musculoskeletal peptide research describes encouraging animal findings alongside scarce rigorous human safety data. More detail about how something might work doesn't make that safety gap smaller. And GLOW adds the unanswered question of what happens when the ingredients meet in one blend.
When a claim sounds impressive, try finishing this sentence: researchers tested this substance, in this setting, and found this change. If a piece is missing, the answer can stay open. There's no need to make the paper say more than it does.